NCT05704283 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
| NCT ID | NCT05704283 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Mayo Clinic |
| Condition | Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2023-02-14 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 55 participants in total. It began in 2023-02-14 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in evaluating lymph nodes in patients with breast cancer. Ultrasound uses high-frequency sound waves to generate images of the body.
Eligibility Criteria
Inclusion Criteria: * Patients with lymph node biopsy or lymph node clip placement as per routine clinical care. * Age of 18 or older. Exclusion Criteria: * Vulnerable subjects such as prisoners and adults lacking capacity to consent.
Contact & Investigator
Shigao D Chen, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT05704283 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05704283 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05704283 currently recruiting?
Yes, NCT05704283 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT05704283 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT05704283 clinical trial?
NCT05704283 is sponsored by Mayo Clinic. The principal investigator is Shigao D Chen, PhD at Mayo Clinic in Rochester. The trial plans to enroll 55 participants.